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It is time once again for the latest issue of LABRAD. 
This edition is non-thematic and includes various 
fresh and newfangled topics. There is an update on 
the revised nomenclature of Encapsulated Follicular 
Variant of Papillary Carcinoma which has shifted the 
paradigm of treatment. 
Hereditary thrombophilia refers to a group of 
inherited disorders that is characterized by a 
defect or deficiency in the natural anticoagulant 
mechanisms and thus increased predisposition to 
thromboembolism. There are a number of causes for 
this disease and a proper screening through history 
and physical examination will initially pave the way 
for further testing. The article on Thrombophilia in 
this issue, adequately describes the process.  
Hemorrhage remains a major cause of potentially 
preventable deaths. Rapid transfusion of large 
volumes of blood products is required in patients 
with hemorrhagic shock which may lead to a unique 
set of complications. Timely recognition of these 
complications and efficient management are vital 
for successful outcomes. The article on massive 
transfusion describes all these complications along 
with monitoring and prevention.
Prealbumin is a nutritional biomarker which can 
accurately assess the nutrition status for which assays 
are available in the laboratory. There is an article 
which elaborates the clinical association and purpose 
for diagnostic evaluation.
There is also an interesting collaboration of 
Pathology and Radiology with respect to a case of 
Parosteal osteosarcoma and we hope that you enjoy 
reading this one. 
Ending on the thought provoking phrase by Socrates 
“The only true wisdom is in knowing you know 
nothing”, we sincerely hope that you will benefit 
from these articles written by our residents and 
consultants and continue to support us as always….
Bonne lecture!!
Dr Natasha Ali
Editor, LABRAD
From the Editor’s Desk
Another term has been proposed by the Chernobyl 
group of pathologists as Well differentiated tumor 
of uncertain malignant potential; WDT-UMP  but 
because of lack of standardized & reproducible 
criteria the term has not been widely adopted. 
The Follicular variant of Papillary carcinoma of the 
thyroid (FVPTC) has two subgroups; Encapsulated 
& Invasive (Figure 1). The FVPTC has an almost 
exclusive follicular pattern with nuclear features 
of PTC i-e nuclear crowding, clearing, groves & 
The thyroid is the most frequent  endocrine organ 
to harbor cancer, Papillary carcinoma being the 
most frequent one. Other differentiated cancer 
includes Follicular carcinoma, including Hurthle cell 
carcinoma as well. The C-cell derived Medullary 
carcinoma accounts for approximately five percent of 
thyroid cancers. The incidence of thyroid cancers has 
shown three fold increase & PTC is the main type of 
this rise. The follicular variant of papillary carcinoma 
was first described by Dr. Rosai in 1977. Now 
accounting for approximately 25 percent of the PTC. 
Revised Nomenclature of Encapsulated 
Follicular Variant of Papillary Carcinoma; 
Now NIFTP in 2016
Dr Saira Fatima 
Histopathology
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pseudoinclusions. The nuclear changes may be 
patchy or diffuse. They have a capsule of variable 
thickness in encapsulated FVPTC (Figures 2 & 
3). Capsular sampling should be done in a similar 
manner as for follicular adenoma/carcinoma. 
These tumors do not show high nuclear grade, 
necrosis or increased mitoses (Tables 1 & 2). The 
prognosis of the two subtypes varies in terms of 
metastatic potential & recurrence, being virtually 
absent in encapsulated FVPTC. Therefore, biologic 
behavior is more in line with follicular adenomas/
carcinoma depending upon capsular or vascular 
invasion. Whereas invasive FVPTC shows infiltrative 
growth involving adjacent tissue, behaves more 
like ordinary PTC. The molecular alterations 
are detected in similar fashion. Encapsulated 
FVPTC has lack of BRAF V600E mutations, 
frequent RAS mutations approx. 36 persent and 
rare PAX8/PPARG alterations. Invasive FVPTC 
has more frequent  BRAF V600E & less common 
RAS mutations & RET/PTC rearrangement. 
The molecular profile also supports the clinical 
behavior differences & status of two distinct 
Table 1: Diagnostic Criteria for Nuclear features of Papillary Carcinoma & NIFTP (2016 SCPMG Thyroid NIFTP Education Module)
Major Features Minor Features Features NOT seen/Exclusion criteria
1. Dark/hypereosinophilic colloid
2. 1rregularly-shaped follicles
3. lntratumoral acellular, eosinophilic fibrosis
4. “Sprinkling” sign  (multifocal involvement  
 within a single nodule)
5. Follicles cleft from stroma
6. Multinucleated giant cells with in follicles
1. Encapsulation or clear demarcation
2. Follicular growth pattern 
 (<1% papillae) 
3. Nuclear Features of PTC (Score 2 or 3): 
l Enlargement/crowding/overlapping
l  Elongation
l  Irregular contours
l Grooves
l  Pseudoinclusions
l Chromatin clearing
1. “True” papillae >1%
2. Psammoma bodies
3. Infiltrative border (capsular or lympho 
 vascular invasion)
4. Tumor necrosis
5. High mitotic activity (>3/1 0 HPFs)
6. Cell/morphologic characteristics of other  
 variants of PTC
Figure 1:  An encapsulated follicular neoplasm. There is no capsular 
invasion. (2016 SCPMG Thyroid NIFTP education module)2016 SCPMG 
Thyroid NIFTP education module
Figure 2:  Exclusive follicular pattern with irregularity of follicles, 
nuclear overlapping & clearing. ( 2016 SCPMG Thyroid NIFTP 
education module)
Figure 3: Nuclei are elongated, crowded & irregular. Nuclear grooves 
are prominent. (2016 SCPMG Thyroid NIFTP education module)
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3) Chromatin Features
•  Chromatin clearing
•  Margination to nuclear
 membrane
•  Glassv nuclei
Thromboembolic abnormalities are influenced by 
both heritable and environmental factor. The term 
heritable thrombophilia pertains to an inherited 
coagulation abnormality that has increased risk 
of thrombosis. Egeberg et al first reported the risk 
of venous thromboembolism with deficiency of 
Dr Anila Rashid
Haematology and Transfusion Medicine
Heritable Thrombophilia Screening: When & 
in Whom
antithrombin, a naturally occurring anticoagulant in 
1965. Since then, the deficiencies of various other 
naturally occurring anticoagulants have been found 
to be associated with familial thromboembolic 
disorders. In late 80s testing for thrombophilia 
screening became popular in unselected patients and 
1) Size and Shape
•  Enlargement
•  Elongation
•  Overlapping
2) Membrane Irregularities
•  Irregular contours
•  Grooves
•  Intranuclear cytoplasmic  
 inclusions
Nuclear Features Absent/Insufficiently expressed (0) Present/Sufficient (1)
entities. 
After reviewing the long term clinical followup data, 
the Endocrine pathology society at a conference 
held in Boston March 2015 accepted the term Non-
invasive Follicular Thyroid Neoplasm with Papillary-
like Nuclei, NIFTP for Encapsulated FVPTC. 
An international, multidisciplinary study of 109 
patients with non-invasive EFVPTC were followed 
for 10-26 years along with 101 patients of invasive 
FVPTC from five different countries. The digitalized 
histologic slides were reviewed by 24 pathologists 
from seven countries.
The study concluded that noninvasive EFVPTC 
have a very low risk of recurrence or metastasis 
& should be termed as NIFTP. The recommended 
management is lobectomy alone without radioactive 
iodine ablation. This will remove unnecessary total 
thyroidectomy surgeries & their complications. 
Patients will be free of cancer stigma & psychological 
burden associated with such a diagnosis.
Table 2:  2016 SCPMG Thyroid NIFTP Images for Scoring
Nuclear score: Sum of three nuclear features (each 0 or 1)
Thus, total score will vary between 0 and 3
Slight changes not sufficient
to call “present”!
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Massive Transfusion
Dr Imran Ahmed Siddiqui
Haematology and Transfusion Medicine
Massive transfusion is defined as the replacement 
of one total blood volume in 24 hours or the 
replacement of 50 percent of the blood volume in 
three hours. The most common situation leading 
to massive transfusion is trauma. Other situations 
leading to massive transfusion, such as ruptured 
abdominal aortic aneurism, liver transplant, and 
obstetric catastrophes are less frequent.
Complications of Massive Transfusion
Massive blood replacement may be accompanied by 
metabolic and coagulation abnormalities related to 
transfusion volume and infusion rate. 
Hypothermia can incite metabolic and hemostatic 
derangements. Studies have shown that the 
transfusion of one unit of red blood cells with 
a temperature of 4°C can drop the core body 
temperature 0.25°C in an average-sized patient. 
During massive transfusion, the rate of citrate 
delivery may exceed the liver’s capacity for 
its clearance. Metabolic alkalosis can develop 
secondarily to the accumulation of bicarbonate, the 
metabolic by-product of citrate. Citrate toxicity 
will result in hypocalcemia and cause symptoms 
such as tingling, shivering, lightheadedness, tetany, 
and hyperventilation. Rarely, hypomagnesaemia 
associated myocardial depression can be observed 
with severe citrate toxicity. These complications 
are mostly observed in patients with liver failure. 
Citrate-induced hypocalcemia is rarely associated 
with clinical consequences in other massively 
transfused patients. 
Potassium concentrations in PRBCs can range from 
seven to 77 mEq/L depending on age of stored 
blood. Development of hyperkalemia will depend 
on the underlying renal function, severity of tissue 
injury and rate of transfusion. At transfusion rates 
exceeding 100-150 ml/min, transient hyperkalemia 
is frequently seen. Also, acidosis secondary to 
in their relatives without any proven clinical utility. 
A wide range of different tests can be employed 
within heritable thrombophilia profile, although 
these primarily comprise factor V Leiden, activated 
protein C resistance (APCR), protein C, protein S 
and antithrombin.
Several clinical guidelines emerged to guide 
heritable thrombophilia investigations taking into 
account, the age at presentation, site of thrombosis, 
family history, and associated risk factors. 
Apart from selecting the right patient for testing 
many other factors contribute an affects the results 
and interpretation of these investigations.
It is important for clinicians to realize the limitations 
of thrombophilia testing. Thrombophilia screening 
is not only expensive and time-consuming but 
is often performed without a clear idea of what 
to do with the results. Therefore it is important 
that screening is targeted at the right people with 
appropriate timing of the test as these can alter the 
test interpretation. Thrombophilia screening should 
ideally be performed two to three weeks after 
completion of anticoagulation therapy and should 
be avoided during acute thrombotic event or during 
anticoagulation therapy as it may affect the test 
interpretation. 
According to the British Committee for Standards 
in Haematology, the following are the preferred 
indications for heritable thrombophilia screening:
 - First thrombotic event in young age less than  
  40 years of age
 - Unprovoked thrombosis
 - Unprovoked recurrent thrombosis
 - Thrombosis at unusual site
 - Thrombosis with strong family history of  
  unprovoked recurrent thrombosis.
 - Neonates and children with purpura   
  fulminans should be tested urgently for 
  protein C and S deficiency
 - Testing is not recommended in patients with 
  central venous catheter (CVC)-related thrombosis
 - Testing is not indicated in patients with 
  retinal vein occlusion
 - Testing for heritable thrombophilia is not  
  indicated in patients with arterial thrombosis
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hypoperfusion may worsen hyperkalemia. Cardiac 
effects of hyperkalemia are accentuated by 
hypocalcaemia.
Coagulation abnormalities can develop 
secondarily to hemodilution or diffuse intravascular 
coagulopathy. Use of large volumes of asanguineous 
fluids and packed red blood cells during resuscitation 
in hemorrhagic shock will create platelet and 
coagulation factor deficiencies. 
Thrombocytopenia with platelet counts below 
50,000/mm3, hypofibrinogenemia, and coagulation 
factor levels below 25 percent generally occur after 
the replacement of two blood volumes. 
Monitoring and prevention
As volume is replaced, attention must be paid to 
coagulation parameters, platelet count, and metabolic 
status. The coagulation system should be frequently 
monitored with measurements of the PT, aPTT, 
fibrinogen concentration, and platelet count or a 
viscoelastic measure preferably after each five 
units of blood replaced. If the PT and aPTT exceed 
1.5 times the control value, the patient should be 
transfused with at least two units of fresh frozen 
plasma. If the platelet count falls below 50,000/
microL, six units of random donor platelets, or one 
unit of apheresis platelets, should be given.
A high capacity commercial blood warmer should 
be used to warm blood components toward body 
temperature when more than three units are 
transfused. Risk of hyperkalemia can be reduced 
by selecting red cells collected less than five or 10 
days prior to transfusion. Any unit of red cells can 
be washed immediately before infusion to remove 
extracellular potassium.
A Review of Innovance PFA-200 System
Clinical applications:
l Helps to detect inherited, acquired and drug-
 induced platelet dysfunction.
l Detects Von Willebrand disease.
l Assesses the anti-platelet effect of aspirin.
l Evaluates platelet dysfunction in children.
l Evaluates platelet dysfunction in multiple 
 clinical settings such as high bleeding risk 
 surgery, high risk pregnancy and menorrhagia.
l Detects effects of Clopidogril tablets in patients 
 undergoing therapy with a P2Y12-
 receptor antagonist.
Dr Muhammad Hasan
Haematology & Transfusion Medicine
Test CartridgesA bench top instrument that allow rapid detection of 
platelet dysfunction (hereditary and drug induced) in 
citrated human whole blood.
PRINCIPLE OF PFA-200 SYSTEM
Citrated whole blood is aspirated at high shear rates 
through disposable cartridges containing an aperture 
within a membrane coated with either collagen and 
epinephrine or collagen and ADP. These agonists 
induce platelet adhesion, activation and aggregation. 
Platelet plug formed at aperture diminishes and 
finally stops blood flow. Time taken (seconds) from 
start of test until platelets occlude the aperture is 
called Closure Time (CT). CT is an indicator of 
platelet function.
INNOVANCE PFA-200
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Test cartridges:  It has three test cartridges of different composition used for different purposes.  
Test Cartridge Composition Use
2 ug equine Type I collagen
10 ug epinephrine bitartrate
2 ug equine Type I collagen
50 ug  adenosine-5’-
diphosphate (ADP)
20 ug ADP
5 ng Prostaglandin E1 
(PGE1)
125 ug ionic Calcium
No Collagen
Dade PFA 
Collagen/EPI
Test Cartridge
Dade PFA Collagen/
ADP 
Test Cartridge
Innovance P2Y 
Test Cartridge
Primary cartridge used to detect platelet dysfunction induced by intrinsic plate-
let defects, VWD or exposure to platelet inhibiting agents. Can provide effective 
assessment of pre-surgical therapy with DDVAP
Is used to indicate if an abnormal result obtained with Col/EPI Test Cartridge 
may have been caused by effect of ASA or medications containing ASA.
Col/EPI Test Cartridge is sensitive to Aspirin
Is used to detect platelet dysfunction induced by blockade of platelet P2Y12-
receptors in patients undergoing therapy with a P2Y12-receptor antagonist
CARTRIDGE
Col/EPI
Col/ADP
P2Y12
SENSITIVITY
100%
97%
98.5%
SPECIFICITY
97%
92%
93.7%
Advantages of the PFA 200:
l Only small volumes of citrated venous blood [800μL) are needed and so the test is useful 
 for investigating platelet function in children.
l Can be used by non-skilled personnel and is both rapid and automated
l The PFA 200 was designed as a screen to detect problems with primary hemostasis and 
 in part to replace the bleeding time and in this respect it is better standardized.
l Measurement of platelet function at high shear [physiological] rates whereas Light 
 Transmittance Aggregometry (LTA) measures platelet function at low shear rates i.e. less 
 physiological.
l Relatively insensitive to clotting factor deficiencies
l High negative predictive value – i.e. if the PFA200 gives a normal result then with some 
 exceptions primary haemostasis is intact [Exceptions: Storage Pool Disorder, Primary 
 Secretion Defects, mild Type 1 VWD].
l Due to the dedicated cartridge for P2Y12 receptor, Clopidogril resistance can be 
 analyzed.  
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Radiologic-Pathologic Correlation
Osteogenic Tumors
A 28 year female patient presented with long history 
of painless swelling of left upper arm. An x-ray was 
performed which showed a huge heavily calcified 
mass attached to cortex of the humerus with a broad 
base wrapping around it. On the medial side of 
humerus, an incomplete lucency between the tumor 
and underlying bone is seen (Figure 1)
An incision biopsy was 
performed and sent for 
histologic evaluation. 
Histological 
examination showed a 
bone forming tumour 
covered by cartilage 
cap which exhibited 
moderate cellularity 
and atypia (Figure 
2A,B). Beneath 
cartilage cap are 
parallel seams of 
woven bone with 
intervening mildly 
atypical spindle cells 
(Figure 2C,D).
Based on radiological and histological features, a 
diagnosis of Parosteal osteosarcoma was rendered.
Parosteal 
osteosarcoma is a low 
grade malignant bone 
forming neoplasm 
that accounts about 
four percent of all 
osteosarcomas. 
A slight female 
predominance is seen 
and most patients are 
young. Approximately 
two third of cases 
arise on the surface 
of distal posterior 
femur. The department 
of Pathology and 
Laboratory Medicine 
archives has 23 cases of 
parosteal osteosarcoma 
diagnosed over a period 
of 13 years. These 
showed a mean age of 
26 years and 68 percent 
of cases involved distal 
femur. 
Radiological differential 
diagnosis of parosteal 
osteosarcoma are 
osteochondroma 
and conventional 
osteosarcoma. A 
radiolucent line 
separating base of tumor 
from adjacent cortex is seen in approximately 58 
percent cases of parosteal osteosarcoma. Most cases 
of osteochondroma attach to underlying cortex by a 
pedicle, not a broad base. Conventional osteosarcoma 
extensively involves the cortex with secondary 
involving periosteum.
Histologically parosteal osteosarcoma differentiated 
from osteochondroma by presence of parallel seams 
of woven bone containing intervening mild atypical 
spindle cells. Osteochondroma has trabeculae of mature 
lamellar bone with intertrabecular spaces containing 
either fatty or hematopoietic marrow. The cartilage 
cap in osteochondroma has columnar arrangement 
of chondrocytes. Approximately 50 percent cases of 
parosteal osteosarcoma cartilage differentiation either 
in the form of cartilage nodules or a cartilage cap. The 
cartilage cap however lacks columnar arrangement.
Around 15-25 percent cases of parosteal 
osteosarcomas show dedifferentiation in the form 
of high grade sarcoma. Recent advances show 
CDK4 and MDM4 gene amplification in >85 
percent cases of parosteal osteosarcoma. Prognosis 
is excellent with 91 percent overall survival at five 
years. Around six percent cases metastasize by five 
years and 11 percent at 10 years which are mostly 
dedifferentiated.
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology
Figure 1
Figure 2A,B
Figure 2C,D
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A useful biomarker of nutritional status should 
readily respond to variations in nutrient intake, 
remain unaffected by other diseases, easy analytical 
procedures available, comparatively low-cost, and 
possess a shorter half-life. Traditionally, albumin 
levels have been in common utilization by clinicians 
and laboratories globally as predictor of nutritional 
status, but they themselves suffer from certain 
limitations including lack of significant response 
to recent fluctuations in nutrition; retain a longer 
half-life (20 days) and moreover also get influenced 
by hydration status and renal parenchymal diseases. 
Albumin characteristically takes 14 days to return to 
baseline when the pool has been depleted. 
Published literature has suggested prealbumin or 
transthyretin as one such nutritional biomarker which 
can accurately assess the nutrition status. It is mainly 
produced by the liver and assays of quantification 
are readily available for lab utilization, have a short 
half -life (two days), less affected by liver disease, 
and have one of the highest ratios of essential to 
nonessential amino acids, making it a distinct marker 
for assessing malnutrition. 
Clinical associations with high or low serum 
prealbumin concentrations: 
Serum concentrations of prealbumin are influenced 
by a large number of factors
A)  Causes of increased concentrations of   
 prealbumin
 1. Increased synthesis: exogenous 
  corticosteroids or anabolic steroids; 
  NSAIDS; insulin-like growth factor-1 (IGF- 
  1), either endogenous or exogenous. 
 2. Decreased catabolism: chronic renal failure;  
  renal tubular damage. 
 3. Distributional or hydration changes: standing  
  position prior to blood sampling; acute
  dehydration. 
B)  Causes of decreased concentrations
 1. Age: infancy, childhood, and advanced age.
 2. Decreased synthesis: acute phase response  
  (infection, inflammation, trauma,   
  malignancy, etc.); administration of IL-6; 
  estrogens (endogenous or exogenous); acute 
  total starvation;  moderate to severe liver 
  disease (may be due in part to inflammation 
  and/or estrogen); thyroid disease, especially 
  endemic goiter. 
 3. Distributional changes: increased vascular 
  permeability; ascites or pleural fluid; 
  recumbent position prior to blood sampling 
  (e.g., in bedridden patients); acute   
  hemodilution. 
 4. Increased loss/catabolism: acute blood loss; 
  protein-losing enteropathy; nephrotic syndromes.
Intended use of Prealbumin
Prealbumin is primarily used for evaluating 
nutritional status, chiefly in monitoring the response 
to nutritional support in the acutely ill patient. 
Furthermore, Prealbumin response has found to have 
a significant correlation with patient outcome making 
it a useful prognostic marker. In a 1995 consensus 
statement a panel recommended checking serum 
Prealbumin levels in all patients admitted to the 
hospital with malnutrition or nutritional risk factors 
such as advanced age, diabetes, hypertension, and 
renal disease. The panel also recommended that 
patients with levels <15 mg per dL (150 mg per L) 
receive a consultation from the hospital’s nutritional 
team. Prealbumin has also been proven to be a good 
indicator of probabilities of developing re-feeding 
syndrome upon commencement of refeeding, via 
either the enteral, parenteral or oral routes.
Thus to conclude Prealbumin should therefore be 
employed as a pivotal component of an overall 
assessment strategy as it is a sensitive biomarker 
of insufficient nutrient intake. Furthermore its 
levels should be interpreted with caution in acute 
alcoholism, steroid use, and zinc deprivation. 
Additionally serial monitoring of Prealbumin 
assessed twice weekly during hospital stay can well 
sensitize the physician about the patient’s nutritional 
status. 
Pre Albumin or Transthyretin - A Useful 
Biomarker in the Assessment of Malnutrition
Dr Sibtain Ahmed
Chemical Pathology
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Urinary Tract Infections (UTIs) in Children: 
A Pictorial Guide  
Dr Fizza Farooqui                                                         
Microbiology
Table 1: Diagnostic criteria for UTI in children
National Institute of Health and Clinical Excellence 
(NICE)1:
American Academy of Pediatrics (AAP)2: Pyuria and growth of ≥50,000 colony forming units of a single 
urinary pathogen.
Unexplained fever >38°C
Test urine WITHIN 24 hours!!
Age Group
 
<3 months
 
3 months - <3 
years
 
>3 years
Dipstick 
analysis (D/R)
-
Debatable
√
Culture (Clean catch/ 
suprapubic/ in/out catheters)
√ (+ other sites e.g. blood, 
cerebrospinal fluid)
√
√
Urgent microscopy (>5 cells per high 
power field)
√
√
√
Urine culture: 24 hour growth on CLED medium. >105 colony forming units of lactose fermenting gram 
negative rods
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Other Management 
NICE AAP
Ultrasound of kidneys and bladder for structural anomalies
Voiding cystourethrogram for complex cases
Regular bladder emptying
General hygiene measures
Adequate fluid intake
Breast feeding
Circumcision
Thus, a high index of suspicion, appropriate sample collection and testing followed by regular follow up to 
prevent recurrent UTI remain the mainstay for management of urinary tract infections in children.
Method validation is the process of “establishing 
documented evidence” which provides high degree 
of assurance that product (equipment/analyte) 
meets the requirements for the intended analytical 
applications. The definition used for “validation” 
in the ISO standard 8402 is “confirmation by 
examination and provision of objective evidence that 
the particular requirements for a specific intended 
Validation of Test Methods in a Clinical 
Laboratory: A Brief Overview of the 
Concepts, Aims and Procedures
Ms Farhat Jahan
Chemical Pathology 
Collection
NICE AAP
In/out catheter or suprapubic 
aspiration 
Clean catch urine
Urine collection bags and pads 
(contamination!)  
In/out catheter or suprapubic aspiration
Empiric Antibiotic Therapy
NICE AAP
Antibiotic based on desired route of administration, local 
antibiogram, then susceptibility results for 7-14 days  
NONE!! (↑ antibiotic resistance, inconvenience, lack 
of compliance, ↑cost )
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 methods
It is a series of processes through which we test 
our system to verify or validate the performance 
specifications claimed by the manufacturer. A full 
validation is needed for new methods or when 
major changes to an existing method affect the 
scope. Partial validation is performed on previously 
validated methods that have undergone minor 
modifications. Generally, fewer tests are needed 
and are based on the potential effects of the 
modifications. Cross-validation can be used as means 
of assessing inter-laboratory execution of the same 
method.
A basic process of initiating and implementing 
method validation in a clinical laboratory is shown in 
figure 1. The main focus of whole method validation 
process is identifying the sources of potential 
analytical errors, including both random 
error and systemic error. Where random 
error is the amount of inherent variation 
in the method and systemic error is the 
difference from the true value. 
The various performance characteristics 
which are evaluated during method 
validation process include:
l Accuracy: Closeness of the   
 agreement between a test result and  
 the true or target value. It is 
 expressed as the difference between 
 the averages results obtained from  
 two different methods (Bias). It   
 is a measure of systemic error.
l Precision: Precision, repeatability or 
 reproducibility is the degree of  
 agreement among repeated 
 measurements (closeness of 
 measurements to each other or   
results consistency) of the same 
substance on the same sample, or 
on separate samples collected as 
 close as possible in time and place. Precision is a 
 measure of random error. 
l Linearity: It is the ability of method to produce 
 the test results that are proportional to the 
 analyte concentration and the relationship 
 between the observed and target value can be 
 graphically represented by a straight line.
l Analytical Measurement Range: Range of  
 numeric results a method can produce without  
use are fulfilled”. Without method validation 
experiments, there can be no assurance that the 
results reported are reliable and fit for the purpose 
defined. All laboratory tests/equipment must be 
validated before being introduced in patient testing 
to ensure that the values results reported meets the 
clinical expectations with an anticipated degree of 
reliability. Once the process is all equipment/analytes 
needs to be revalidated following any change in 
reagents, instrumentation or protocol and to ensure 
quality assurance (QA) after a certain period of 
time. Method validation is required to evaluate and 
document inaccuracy and imprecision in a method 
performance. The clinical requirements should be 
pre-determined prior to initiating method validation 
studies (figure 1). Tests using complex methodology 
usually require more thorough validation studies than 
moderately complex or simple methods.
These are certain conditions when method validation 
may be required:
l New method is developed/introduced in clinical  
 laboratory 
l Modification of established methods
l Every six months to ensure optimal performance  
 of methods
l When established methods are transferred to  
 different test facilities 
l For comparison of two or more laboratory test  
Figure 1: Flow Chart Showing Basic Process of Method Validation of a New Lab Test at a 
Clinical Laboratory
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Urolithiasis refers to the formation of stones anywhere 
in the urinary system. These stones may form as result of 
one or more of several factors that include an unhealthy 
diet, infections, inherited metabolic disorders and 
lithiasis due to secondary reasons from other illnesses. 
Renal stones are usually classified according to 
their composition. Different conditions can cause 
differences in the composition of the stones. 
Therefore stone analysis is important to better 
understand the cause of the stones and treat them 
appropriately. Renal stones are analyzed to evaluate 
the constituents of a stone, to help determine the 
cause of its formation and also to guide treatment and 
prevent its reoccurrence. 
Analysis of Kidney Stone Composition
According to American Urological Association 
Guidelines, all patients with history of urolithiasis 
should have at least one stone analyzed before 
initiating treatment. Second analysis is only indicated 
if physician suspects change in stone composition. The 
recommended techniques for renal stones analysis are: 
l X-ray crystallography 
l Infrared spectroscopy
At section of Chemical Pathology, Department of 
Pathology and Laboratory Medicine, Aga Khan 
University, renal stones are now analyzed by Fourier 
transform infrared spectroscopy (FTIR), a semi 
quantitative methodology. It helps identify not only 
composition of renal stones but can help differentiate 
between compositions of stone surface and core 
(nidus). Composition of stone core or the nidus is 
important in managing patient, as it may be entirely 
different from that of the peripheral layers and 
may lead to changes in management of patient. For 
accurate analysis proper collection and transport of 
stone is necessary.
Special Instructions for Collection and Transport 
of Kidney Stones
l Specimen source is required and should be   
 mentioned on the request slip.
l The entire stone should be sent for analysis.
l Stone must be sent clean and dry (ambient   
 temperature preferred for transport).
l The stone should not be directly placed in a bag.  
 If specimen is received in a bag, either transfer 
 the stone into a screw-capped plastic container 
 or place the bag containing stone in screw-
 capped plastic container.
Clinical Significance of Stone Composition 
Analysis in Urolithiasis Management
Dr Hafsa Majid and Dr Abdullah Saleem Ghelli
Chemical Pathology
 any special specimen pre-treatment, such as dilution
 that is not part of the usual analytic process.
l Limit of Detection: It is the lowest amount of 
 analyte which can be detected, but not 
 necessarily quantitated as an exact value.
l Limit of Quantitation: The lowest    
 concentrations of an analyte in a sample that can 
 be quantitatively determined accurately with 
 suitable precision. 
l Analytical Specificity: The ability of a method 
 to detect only the analyte that it was designed 
 to detect without interference from some other 
 substances. 
l Analytical Sensitivity: The lowest concentration 
 of the analyte which the test can reliably detect 
 as positive in the given matrix”.
    
l Reference Intervals: in this method validation 
 study healthy population is tested for certain 
 analytes in order to characterize the expected 
 range of test values for that population. The 
 laboratory should establish or verify existing 
 reference intervals for each method and species 
 before reporting results.
All activities conducted during validating a test 
need to be documented. Documenting the whole 
method validation processes along with evidence is 
important before implementing a method in service. 
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Causes 
• Hyperoxaluria 
• Inherited metabolic disorder of  
 oxalate 
• Low water intake or dehydration
• Hypercalciuria
• Hypocitraturia 
• Low water intake or dehydration
• High salt consumption 
• UTI (urea splitting bacteria)
• Hyperparathyroidism, Distal 
 Renal tubular acidosis (low urine  
 pH)
• UTI (Alkaline urine pH)
• Other metabolic disorders
• UTI (urea splitting bacteria)
• Alkaline Urine pH
• Bowel disease
• Hyperuricosuria
 
Inherited cystinuria
Inherited xanthinria
Inherited metabolic disorder
Long term treatment with specific 
drug
Stone Type
Calcium 
oxalate 
Ammonium 
hydrogen 
phosphate
Calcium 
phosphate
Uric acid
Genetic Stones
Drugs related 
stones
S#
1. 
2. 
3.
4. 
5. 
6. 
Subtypes
Calcium oxalate 
Monohydrate 
(Whewellite)
Calcium oxalate 
Dihydrate 
(Weddellite)
Struvite
Brushite, Dahllite
Uricite, ammonium 
urate
Cystine 
Xanthine 
2,8-dihydroxyadenine
Management
• ESWL for Wedellite 
• Surgical removal for hard Whewellite  
 stone 
• Enzymes replacement in inherited   
 metabolic disorders 
• Increased fluid intake
• Hydrochlorthiazide (for increased Ca)
• Citrate supplementation
• Pyridoxine
Surgery + antibiotics
• ESWL for Dahllite 
• Brushite extremely hard stones 
 resisting ESWL, may require 
 chemolytic treatment or open surgery
• Urine alkalinization
• Antibiotics
• Purine restriction
• Allopurinol
• Cystine crystallization 
 preventive drugs
• High fluid intake, >3 L per day
• Surgical removal for large Cystine   
 stones
• Purine restriction
• High fluid intake
• High fluid intake
• Uricosuric drugs
• Stop the causative agent
• High fluid intake
Table: Types of Renal Stone, their Causes and Management.
l Following stones would be rejected: embedded 
 in tissue, sent with collection devices, sent in 
 fluid-filled containers, or sent with significant 
 non-stone debris.
Management of Renal Stones
Medical treatment of renal stones involves supportive 
care and administration of agents, such as analgesics, 
NSAIDS, antidiuretics, antibiotics, alkalinizing agents 
etc. While for stones that are ≥7 mm and are unlikely 
to pass spontaneously may require some type of 
surgical procedure, such as percutaneous nephrostomy, 
extracorporeal shockwave lithotripsy (ESWL), 
ureteroscopy, percutaneous nephrostolithotomy etc. 
The composition of a stone can be an important factor 
in its disintegration by lithotripsy and subsequent 
elimination of fragments. Stones made of uric acid 
and calcium oxalate dihydrate have a better coefficient 
of fragmentation than those made of calcium oxalate 
monohydrate and cystine. Hard stones respond 
poorly to ESWL; e.g. stones made of cystine, calcium 
oxalate monohydrate, and brushite. Nowadays 
open surgery is usually reserved for cases with 
anatomical abnormalities or in cases where ESWL 
is contraindicated. In cases of inherited metabolic 
disorders, use of enzyme replacement or gene therapy 
may be required; types of stones, their causes and 
management are summarized in table below.
To conclude the renal stone composition is not only 
important for guidance of treatment, but it can also play 
an essential role in determining the underlying cause 
of urolithiasis. There are many underlying causes of 
renal stones and knowing the composition of a stone 
influences clinical decisions. Thus, instructing the patient 
to retrieve a passed stone or instructing the urologist, 
who is performing a stone-related procedure, to save and 
send a stone fragment for analysis is an important part of 
the approach to prevent recurrent stone formation.
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